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BACKGROUND: Different adiposity traits may be causally related to hypertension in different ways. By using genetic variants as 
randomly allocated proxies for studying the effect of modifying adiposity traits, the Mendelian randomization approach can 
be used to investigate this.
METHODS AND RESULTS: In this study, we used 4 different genetic risk scores (GRS; GRS- BMI565, GRS- WHR324, GRS- VAT208, 
GRS- BF81) including hundreds of single nucleotide polymorphisms associated with body mass index, waist- to- hip ratio, vis-
ceral adipose tissue, and body fat, respectively. These were applied as instrumental variables in Mendelian randomization 
analyses. Two Swedish urban- based cohort studies, the Malmö Diet and Cancer, and the Malmö Preventive Projects were 
used to obtain genetic association estimates with blood pressure (BP). In both the Malmö Preventive Projects and Malmö Diet 
and Cancer studies, except for that for body fat, all of the genetic risk scores were significantly associated with systolic BP and 
diastolic BP, but with different magnitudes. In particular, in both cohorts, each standard deviation increase in the genetic risk 
score made up by the 324 single nucleotide polymorphisms associated with waist- to- hip ratio was associated with doubling 
of the likelihood of hypertension prevalence at baseline. However, only the genetic risk score made up by the 565 SNPs as-
sociated with body mass index was significantly associated with hypertension incidence during 23.6±4.3 years of follow- up 
in the Malmö Preventive Project.
CONCLUSIONS: We support a causal link between genetically mediated adiposity, especially waist- to- hip ratio and body mass 
index, and BP traits including hypertension prevalence and, for the first time to our knowledge, hypertension incidence. The 
differences in magnitude between these associations might suggest different mechanisms by which different adiposity affects 
BP/hypertension and consequently may indicate that tailored interventions are needed to reduce cardiovascular risk.
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Obesity and hypertension are 2 of the main causes of noncommunicable diseases and mortality worldwide.1,2 It is well known that adiposity it-
self is a risk factor for hypertension,3 but how different 
measures of obesity influence blood pressure (BP) is 
less clear.
On one hand, genome- wide association studies 
have now pinpointed hundreds of genetic variants 
that are associated not only with body mass index 
(BMI), but also with waist- to- hip ratio (WHR), visceral 
fat mass, and body mass distribution.4– 7 On the other 
hand, Mendelian randomization (MR) studies have 
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supported that BMI and other adiposity measures are 
causally related with hypertension.8,9
Adiposity is a complex trait, whose genetic com-
ponent is influenced by the contribution of many 
different loci. From the latest genome- wide associ-
ation studies, the number of genetic variants (single 
nucleotide polymorphisms [SNPs]) found to be as-
sociated with different measures of body fat distri-
bution have exponentially increased.5,7 A genetic risk 
score (GRS), obtained by summing up weights and 
risk alleles of the SNPs associated with the trait, is 
a powerful tool to capture the genetic component of 
complex phenotypes.10
However, even if the GRSs obtained in large 
genome- wide association studies and meta- analyses 
were validated in well- powered studies, they need 
replication in other independent samples to assess 
the reproducibility of the genome– phenotype asso-
ciation.11 The objective of an MR analysis is to test a 
causal hypothesis, and the genetic information that 
we used in the form of a GRS represents the instru-
mental variable (IV) that is linked to the outcomes only 
through the endogenous variables (the adiposity mea-
sures).12,13 An MR design can reduce reverse causality 
and confounding.
The MDC (Malmö Diet and Cancer) and the MPP 
(Malmö Preventive Projects) studies are 2 large urban- 
based cohort studies based in Malmö in southern 
Sweden in which >27  000 participants were geno-
typed. In the 2 samples, different measures of adipos-
ity (BMI, waist circumference, hip, and body fat) as well 
as BP were recorded. In the MPP study, there is also 
the possibility to evaluate hypertension incidence (not 
only prevalence) during follow- up, because this co-
hort was reexamined 23.6±4.3 years after the baseline 
exam.
Thus, the aim of the present study was to evalu-
ate the association of different measures of genetically 
mediated adiposity with different BP- related traits, in-
cluding hypertension prevalence and incidence, using 
an MR design.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Cohorts
Malmö Diet and Cancer Study
Cross- sectional BP and hypertension prevalence 
at baseline were studied in the MDC study, a large- 
scale urban population- based cohort consisting of 
30 447 individuals (aged 58±7.6 years) from Malmö, 
Sweden. Of these, 29  386 were genotyped for 
genome- wide association studies. Men aged 46 to 
73 years and women aged 45 to 73 years, included 
between 1991 and 1996, were included.14,15 Ethical 
permission for the MDC study was obtained from the 
ethical committee at Lund University (LU 51– 90 and 
DNR 652/2005), and all participants provided written 
informed consent.
Malmö Preventive Project
Hypertension prevalence and incidence were studied 
in the MPP, an urban- based prospective study with 
BP measurements available, both at a baseline exam, 
CLINICAL PERSPECTIVE
What Is New?
• Different genetically determined adiposity traits 
(eg, body mass index, waist- to- hip ratio) are po-
tentially causally linked to blood pressure and 
hypertension but with different magnitudes.
What Are the Clinical Implications?
• Interventions targeted to body mass index and 
waist- to- hip ratio may also decrease blood 
pressure.
Nonstandard Abbreviations and Acronyms
2SLS 2- step least squares
BF body fat
DBP diastolic blood pressure
GRS genetic risk score
GRS- BF81 genetic risk score made up by 
84 SNPs associated with body 
fat
GRS- BMI565 genetic risk score made up by 
565 SNPs associated with body 
mass index
GRS- VAT208 genetic risk score made up by 
208 SNPs associated with 
visceral adiposity tissue
GRS- WHR324 genetic risk score made up by 
324 SNPs associated with 
waist- to- hip ratio
IV instrumental variable
MDC Malmö Diet and Cancer
MPP Malmö Preventive Project
MR Mendelian randomization
SBP systolic blood pressure
VAT visceral adiposity tissue
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including 33  346 citizens from Malmö, Sweden be-
tween 1974 to 1992, and 18  240 at a reexamination 
between 2002 and 2006.16 Of those, 9367, who were 
included also in the MDC study, underwent genome- 
wide association studies genotyping. The ethics com-
mittee of Lund University approved the study protocols 
(DNR 2009/633), and all participants provided written 
informed consent.
Characteristics of the 2 cohorts are presented in 
Table S1.
BP Measurement
In the MDC cohort at baseline, BP was measured 
manually once in the supine position after 5  min-
utes of rest. To deal with the cofounding of the an-
tihypertensive treatment on BP, we used a stepped 
addition method, in which 8/4, 14/10, 20/16, and 
26/22 mm Hg were added to systolic BP (SBP)/dias-
tolic BP (DBP) in the presence of 1, 2, 3, or 4 medica-
tions, respectively.17
In the MPP cohort, at the baseline investigation, 
BP was measured after 1 minute of resting in the 
supine position, followed by another measurement 
after 1  minute in an upright standing position. This 
procedure was repeated also after 10  minutes of 
resting. For those subjects with a least 3 valid mea-
surements, BP values were averaged and used for 
the analysis. At reinvestigation (after a mean fol-
low- up time of 23.0±4.7 years), 2 measures in the su-
pine position were recorded. For those subjects with 
at least 2 valid measures, we used the averaged BP 
values. Both SBP and DBP were increased respec-
tively, using a fixed addition adjustment method by 
15 and 10 mm Hg in the presence of antihypertensive 
treatment,17 because the number of medications was 
not available.
In both cohorts, Korotkoff sound Phase I was de-
fined as SBP and Phase V as DBP.18
In both cohorts, hypertension was defined as hav-
ing either SBP or DBP >140 or >90 mm Hg, respec-
tively, or taking antihypertensive drugs, in line with 
current European guidelines.2 Hypertension preva-
lence could be evaluated in both the MDC and MPP 
cohorts at baseline, whereas in the MPP cohort, hy-
pertension incidence at the reinvestigation survey 
was also investigated. For this analysis, individuals 
who were already hypertensive at baseline (n=3135) 
were excluded.
Adiposity Measurements
In both cohorts, height and weight were measured by 
trained nurses, as previously described.19,20 BMI (in 
kilograms divided by height in meters squared) was 
computed as weight divided by squared height. Waist 
circumference (in centimeters) was measured between 
the lowest rib margin and the iliac crest, and the hip 
circumference (in centimeters) as the largest circumfer-
ence between the waist and thighs. WHR was com-
puted. In the MDC cohort, the percentage of body fat 
(BF) was estimated with bioelectrical impedance ana-
lyzers according to the manufacture’s algorithm (BIA 




A GRS for BMI (GRS- BMI565), a GRS for WHR (GRS- 
WHR324), a GRS for predicted visceral adiposity tis-
sue (VAT) (GRS- VAT208), and a GRS for BF distribution 
(GRS- BF81) were constructed including, respectively, 
565, 324, 208, and 81 independent SNPs retrieved 
from the most recent meta- analyses.5– 7 The scores 
were weighted for the β coefficients reported in the 
primary studies.5– 7 Information about the studies can 
be found in Table S3.
The 4 GRSs (GRS- BMI565, GRS- WHR324, GRS- 
VAT208, and GRS- BF81) were used as IVs in the MR 
analysis.
Exposure
BMI was used as the exposure trait for the GRS- BMI565 
and GRS- VAT208 in both the MPP and MDC cohorts, 
because VAT measure was not available in the 2 co-
horts; and the WHR was used as the exposure trait 
for GRS- WHR324. In the MPP cohort, BMI was used as 
the exposure trait for GRS- BF81 instead of BF, because 
that measure was not available.
In the MDC cohort, the percentage of body fat was 
used as the exposure trait for GRS- BF81.
Individual- Level Data
For continuous outcome (SBP and DBP at baseline 
and at reinvestigation), 2- step least squares (2SLS) 
regression was used to assess the causal associa-
tion of the 4 GRSs. The 2SLS consists of 2 regression 
steps. In the first step, the exposure is regressed on 
the instrumental variable, and in the second step, the 
fitted values obtained from the first regression step are 
used as independent variables in the regression on the 
outcome.21
For binary outcomes (hypertension prevalence and 
incidence), we used the analog of 2SLS consisting of 
2 sequential regressions, with the difference that the 
second step consists of logistic regression of the fitted 
values from the first step on the outcome.21
The exposure traits (BMI, WHR, BF) and the out-
comes (SBP, DBP) have been used as standardized 
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When dealing with multiple instrumental variables, an 
alternative approach to the aggregation in a GRS is to 
use the estimates from each of the instrumental vari-
ables using summarized data analysis, as in a meta- 
analysis.22 With the increasing number of variants used 
in MR investigations, it is increasingly unlikely that all 
variants are valid IVs.23
Sensitivity Analysis
The inverse- variance weighted method, MR- Egger, and 
weighted median were used as sensitivity analyses in 
the MDC cohort to assess the robustness of any casual 
finding of the multiple genetic variants involved in the 
construction of the 4 adiposity- trait GRSs to avoid IV 
assumption.24 The inverse- variance weighted method 
is a weighted mean of the ratio estimates and is equal 
to estimates of 2SLS,22 and it is liable to bias if only one 
IV does not satisfy the IV assumption in the presence 
of pleiotropy.23 The weighted- median estimate is simi-
lar to the inverse- variance weighted method, except for 
the use of a weighted median instead of a weighted 
mean, and consistent up to 50% invalid instruments.23 
The MR- Egger allows for estimating the causal ef-
fect, taking into account the instrument strength inde-
pendent of direct effect assumption, which states that 
the pleiotropic associations of genetic variants must 
be uncorrelated with the genetic variant– exposure 
association.23
Software
All analysis was performed using R software (pack-
ages ivpack, MendelianRandomization; R Foundation 
for Statistical Computing, Vienna, Austria)25 and SPSS 
software (version 22.0; IBM, Armonk, NY).
Figure 1. Causal association from the 2- step least squares (2SLS) Mendelian randomization between the genetic risk 
scores (GRSs) and blood pressure traits in the MPP (Malmö Preventive Project) cohort.
Each forest plot shows the causal estimates (β) from the 2SLS regression of the 4 GRSs with baseline (A) and follow- up (B) blood 
pressure outcomes (SBP or DBP) in the MPP cohort for Model 2 (adjustment for age, sex, age2, age×sex). An increase of 1 SD in 
GRS- VAT208 is associated with an SD increase of 0.326 of SBP. DBP indicates diastolic blood pressure; GRS- BF81, GRS for body fat 
associated with 81 SNPs; GRS- BMI565, GRS for body mass index associated with 565 SNPs; GRS- VAT208, GRS for visceral adipose 
tissue associated with 208 SNPs; GRS- WHR324, GRS for waist- to- hip ratio associated with 324 SNPs; SBP, systolic blood pressure; 
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RESULTS
Association of IVs With the Exposures
In Table 1 and Figure S1, the association of each of the 
4 GRSs used as IVs, with their related exposure traits, 
are presented. The contribution to model in terms of R2 
and the F statistic is also reported.
Association With BP Traits
In Table  S4, the results from the MR analysis of the 4 
adiposity GRSs with the continuous traits SBP/DBP 
at baseline are shown for MPP (Table S4 a.) and MDC 
(Table S4 b.). In the MPP cohort (Table  S4 a. and 
Figure 1 A), all of the GRSs with the exception of the 
GRS- BF81 identify significant associations with base-
line SBP and DBP. In the MDC cohort (Table S4 b. 
and Figure 2), the associations with baseline meas-
urements were in line with the results in the MPP 
cohort. In both studies, the GRS- WHR324 shows the 
strongest association, in particular with DBP. At the 
MPP follow- up, only the GRS- BMI565 remains signifi-
cantly associated with the BP- related traits (Table S4 
a. and Figure 1 B).
In Table 2, the associations of the 4 GRSs with the 
prevalence of hypertension are reported. A higher 
odds ratio was found with GRS- WHR324 as com-
pared with other adiposity GRSs for both the MPP 
(Table 2 and Figure 3A) and MDC cohorts (Table 2 
and Figure 3C).
For hypertension incidence in the MPP cohort, after 
the exclusion of participants already hypertensive at 
baseline, only the GRS- BMI565 remained significantly 
associated with incident hypertension (Table 2 and 
Figure 3B).
Results from sensitivity analysis are presented 
in Tables  S5 through S7. As expected, the inverse- 
variance weighted method reflects the results ob-
tained by the 2SLS regression of the GRSs on the 
traits (Table  S4). The latter shows significant asso-
ciations for all scores with both traits except for the 
GRS- BF81. Among the 4 scores, the only score that 
showed a significant MR- Egger method was the 
GRS- WHR324, both for SBP and DBP (Table S8 and 
Figures S2 through S5).
DISCUSSION
Summary of Main Findings
The main finding of the present study is that geneti-
cally proxied measures of adiposity, as condensed in 
specific GRSs, are associated with BP- related traits 
but with different magnitude. In particular, the GRS- 
BMI565 and the GRS- WHR324 were potentially caus-
ally associated with all BP- related traits measured at 
baseline, but the WHR had a higher estimate size. On 
the contrary, at follow- up, the genetically predicted 
association of WHR with BP tends to be attenuated 
and is no longer significant, whereas that of BMI is still 
significant, although all of the associations tended to 
be weaker than in the prevalence analysis. For more 
complex measures of adiposity, such as BF and vis-
ceral fat, their genetic component seems to be more 
limited in determining BP but still significant when hy-
pertension prevalence is evaluated, at least in the MDC 
cohort.
Even if some reasons for these discrepancies can 
stand on the relative weakness of the instrumental 
variables used with some GRSs being stronger than 
others, it is likely that our study can give some clues 
to understanding more deeply the biology of the well- 
known influence of BF on BP. Our data may indicate 
that the effect of BMI is important, but with low magni-
tude throughout midlife to old age being recognizable 
in people aged in their 40s and 50s (the average age 
in the MPP cohort was 45±7.4 years and in the MDC 
cohort was 58±7.6 years), but also in older people; the 
Table 1. Association of the 4 GRSs (Expressed as per 1- SD Increment) With Their Related Exposure Traits (Expressed as 
SD) at Baseline in the MPP and MDC Cohorts
MPP MDC
β (95% CI) P Value R2 F β (95% CI) P Value R2 F
BMI BMI
GRS- BMI565 0.201 (0.179– 0.218) 8.0E
−86 0.005 393 0.200 (0.189– 0.211) 3.4E−263 0.04 1226
WHR WHR
GRS- WHR324 0.086 (0.065– 0.107) 4.8E
−16 0.007 66 0.046 (0.034– 0.057) 4.7E−15 0.002 61
BMI % BF
GRS- BF81 0.063 (0.043– 0.083) 9.5E
−10 0.004 37 0.045 (0.034– 0.057) 1.5E−14 0.002 59
BMI BMI
GRS- VAT208 0.128 (0.107– 0.147) 1.19E
−35 0.016 156 0.136 (0.125– 0.147) 1.12E−121 0.02 555
BF indicates body fat; BMI, body mass index; GRS, genetic risk score; GRS- BF81, GRS for BF associated with 81 SNPs; GRS- BMI565,GRS for BMI associated 
with 565 SNPs; GRS- VAT208, GRS for visceral adipose tissue associated with 208 SNPs; GRS- WHR324, GRS for WHR associated with 324 SNPs; MDC, Malmö 
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average age in the MPP cohort at reinvestigation was 
68±5.8 years). Instead, the contribution to high BP of 
genetically determined abdominal fat, represented by 
WHR, could seem much higher in midlife, overcoming 
the effect of BMI, than later on. However, an analysis 
done by stratifying participants by age in the MDC co-
hort showed an inverse trend for the GRS- WHR324, with 
older individuals more strongly associated with preva-
lent hypertension than younger individuals, suggesting 
a possible survival bias for the analysis in MPP, where 
participants with especially deleterious GRS- WHR324 













































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Causal association from the 2- step least squares 
(2SLS) Mendelian randomization between the genetic risk 
scores (GRSs) and blood pressure traits in the MDC (Malmö 
Diet and Cancer) cohort.
Each forest plot shows the causal estimates (β) from the 2SLS 
regression of the 4 GRSs with blood pressure outcomes SBP 
(A) or DBP (B) in the MDC cohort for Model 2 (adjustment for 
age, sex, age2, age×sex). An increase of 1 SD in GRS- VAT208 is 
associated with an SD increase of 0.326 of SBP. DBP indicates 
diastolic blood pressure; GRS- BF81, GRS for body fat associated 
with 81 SNPs; GRS- BMI565, GRS for body mass index associated 
with 565 SNPs; GRS- VAT208, GRS for visceral adipose tissue 
associated with 208 SNPs; GRS- WHR324, GRS for waist- to- hip 
ratio associated with 324 SNPs; SBP, systolic blood pressure; 
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Explanation in the Context of Existing 
Research
Our results are in line with those of 2 recent stud-
ies but with some differences.8,9 In an MR analysis, 
including ≈400 000 individuals from the UK Biobank, 
GRS- BMI was found to be associated with BP (β 
[95% CI], 0.19 [0.18– 0.21] for SBP and 0.27 [0.26– 
0.29] for DBP) and to hypertension prevalence (odds 
ratio [OR] [95% CI], 1.10 [1.07– 1.12]) of the same order 
of magnitude of the results we found in the MDC.8 
Also, the association of the genetic component of 
body fat and VAT with hypertension that we found 
in the MDC cohort is consistent with a previous 
MR performed in the UK Biobank study,6,9 despite 
our using BMI instead of VAT as the exposure trait. 
Though the association of the instrumental variable 
GRS- WHR with BP/hypertension is reported in a 
previous study,8 the magnitude of the association is 
much higher in our samples.
A reason for such a difference in magnitude is 
not clear. Differences between the 2 samples in age 
(slightly lower in the UK Biobank study with respect to 
the MDC cohort), ethnicity (more homogeneous in the 
MDC cohort), distribution of sex (higher prevalence of 
women in the MDC cohort), and adiposity and BP traits 
(obesity is more prevalent in the UK Biobank study but 
hypertension is in the MDC cohort) can be postulated 
as a partial explanation.
The debate over which adiposity measure could 
better predict BP or hypertension is still ongoing, even 
in nongenetic studies. There are several pieces of re-
search comparing BMI, waist, WHR, waist- to- height 
ratio (another proxy for central obesity), and VAT show-
ing somewhat contradictory results. Some studies, 
including a couple of meta- analyses, conclude that 
waist- to- height and waist circumference are stronger 
predictors than BMI of future cardiovascular events 
and hypertension.26,27 However, other studies28– 30 
show that BMI is preferentially associated with the in-
cidence of hypertension with respect to WHR. A study 
in young adults (aged 18– 36 years) showed that BMI 
has an equal or better ability to predict adult hyper-
tension as compared with WHR and other adiposity 
measures.31 Moreover, other well- powered analyses 
found that either VAT or BF are strongly associated 
with blood pressure traits32 and the incidence of hy-
pertension.33,34 One problem in this type of study is 
that the adiposity measures are highly correlated with 
each other and associate with differing levels of mea-
surement error that could affect the strength of the 
observed associations.32 MR could be considered an 
advantage in inferring causality, because the use of 
GRS is less susceptible to cofounding from environ-
mental factors or reverse causation with respect to the 
raw trait measures.
Possible Mechanisms and Clinical 
Relevance
Even if it is widely accepted that obesity and hyper-
tension are interrelated and, in particular, the former 
is one of the causes of the latter, from a pathophysio-
logical perspective, it has not been clarified how adi-
posity can influence BP at different ages. It is widely 
accepted that arterial stiffness is one of the main 
factors contributing to higher SBP in older ages. 
Other pathophysiological mechanisms potentially 
linking obesity to high BP refer to metabolic factors, 
endothelial and vascular dysfunction, the hyperac-
tivation of the sympathetic nervous and the renin– 
angiotensin– aldosterone systems, sodium retention 
with a shift of the well- known pressure– natriuresis 
curve toward higher BP levels, and/or other renal 
dysfunctions.35,36 A pivotal player also seems to be 
that VAT becomes resistant to insulin and leptin and 
is the site of altered secretion of molecules and hor-
mones such as adiponectin, leptin, resistin, tumor 
necrosis factor- α, and interleukin- 6.37,38
From the data of our study, it is possible to specu-
late that adipokines especially produced in visceral fat 
and insulin resistance are more important for BP and 
the development of hypertension in midlife, whereas 
total fat is important throughout life and still determi-
nant when arterial stiffness becomes prominent.
In previous MR studies, BMI was also suggested to 
be causally associated with metabolic traits such as 
insulin and inflammation markers such as interleukin- 6, 
which could be associated with hypertension develop-
ment over time.39
Recently, it was shown that SNPs related to VAT 
fat (ie, that is found around abdominal organs) is 
strongly associated also with hypertension. In the 
same study, the heritability of VAT was found to be 
as high as >35%,6 and the genetically determined 
VAT was associated with hypertension spanning 
between 1.81 and 1.89 in men and women, respec-
tively, for the rank- transformed VAT (ie, the VAT after 
rank transformation to standard normal distributions 
for women and men separately) to between 2.17 and 
3.41 for the bias- corrected VAT (ie, VAT corrected for 
measurement errors in a covariate- adjusted model). 
These results are fairly in line with the results in our 
study and similar to that of genetically determined 
WHR. The similar magnitude of the result for WHR 
and VAT underlines the pivotal role of visceral fat for 
high BP.
Strengths and Limitations
Among the strengths of this study are the use of the 
more recently validated GRSs associated with adi-
posity and the MR design that can preserve issues of 
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results were supported in sensitivity analyses that 
are more robust to the presence of variants with plei-
otropic associations.40,41 Finally, to our knowledge, 
this is the first study performing MR between adi-
posity traits and the incidence of hypertension, not 
only prevalence.
Our study has limitations. There is overlap be-
tween the MDC and MPP samples, so that even if 
the 2 studies had their own examinations at different 
time points, one cannot be considered a real replica-
tion of the other. Some GRSs used as instrumental 
variables were weaker than others, especially when 
proxy traits were used as exposure. Thus, some of 
the differences in the associations we found between 
adiposity- related GRSs and BP- related traits could 
be because GRS- BMI565 and GRS- WHR324 were 
better IVs than GRS- BF81 and GRS- VAT208. In addi-
tion, GRS- BF81 and GRS- VAT208 were regressed on 
BMI in the MPP study, necessarily dampening their 
predictive value. Moreover, we have different statis-
tical power for the different BP- related traits (ie, hy-
pertension incidence and prevalence). In addition, 
the hypertension incidence outcome, apart from the 
diminished sample size, could be blurred by the fact 
that the analysis is restricted to people less prone 
to develop hypertension (ie, the ones who have not 
developed hypertension at baseline).
Finally, there is the possible presence of pleiotropy 
among the studied variants. A clear dissection between 
all of the observed adiposity- related traits is not possi-
ble, and several SNPs, especially those encompassed 
in loci that have previously been associated with obe-
sity and BMI, such as the well- known FTO and MC4R 
loci, are common among the different GRSs. All of the 
above- mentioned points, which in some ways could 
be considered intrinsic limitations of the use of genetic 
variants as IVs,42 contribute to reduce the strength 
of the causal inference of our analysis. Any causal 
Figure 3. Forest plot of the association of the 4 genetic risk scores (GRSs) with the prevalence of hypertension at baseline 
in the 2 cohorts and with the incidence of hypertension at follow- up in the MPP (Malmö Preventive Project) cohort.
Each forest plot shows the causal estimates in OR from the 2- stage logistic regression of the 4 GRSs with the prevalence of 
hypertension at baseline in the Malmö Diet and Cancer cohort (A) and the MPP cohort (B), and with the incidence of hypertension at 
follow- up in the MPP cohort (C) for Model 2 (adjusted for age, sex, age2, age×sex). The increase of 1 SD in GRS- VAT208 is associated 
with an OR of 2.01 for hypertension prevalence. GRS- BF81, GRS for body fat associated with 81 SNPs; GRS- BMI565, GRS for body 
mass index associated with 565 SNPs; GRS- VAT208, GRS for visceral adipose tissue associated with 208 SNPs; GRS- WHR324, GRS 
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inference drawn from MR analyses alone should be 
considered tentative.
CONCLUSIONS
We have demonstrated that genetically predicted adi-
posity, and especially genetically predicted WHR and 
BMI, are potentially causally linked to BP and hyper-
tension. Tailored interventions to block this deleterious 
relationship should be pursued and, in particular, in-
tervention to decrease waist circumference and BMI 
throughout life are likely to be most effective.
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Supplementary Tables 






Age, yrs 46.8±6.3 58.0±7.6 
Sex, % Male 55.4 39.7 
BMI, kg/m2 24.3±3.4 25.8±4.0 
Waist to Hip Ratio 0.92±0.09 0.86±0.15 
Body Fat, % - 26.8±7.0 
baseline Systolic Blood Pressure, mmHg 126.5±14.2 141.1±20.0 
baseline Diastolic Blood Pressure, mmHg 85.2±8.7 85.6±10.4 
follow-up Systolic Blood Pressure, mmHg 144.9±20.0 - 
follow-up Diastolic Blood Pressure, mmHg 83.6±10.5 - 
Diabetes at baseline, % 3.8 17.4 
Smoke, % smokers 32.7 62.1 
baseline Hypertensive, % 34.2 61.3 
follow-up Hypertensive, % 63.3 - 
Legend: BMI, Body Mass index; MPP, Malmö Preventive Project; MDC, Malmö Diet and Cancer 
Table S2 Adiposity measurements in the two cohorts. 
Adiposity trait Measurement MDC MPP 
BMI weight (kg)/ height2 (m2); height and weight measured by trained nurses Yes Yes 
WHR waist/hip; i) waist measured between lowest rib margin and iliac crest; ii) hip 
circumference 
Yes Yes 
Body fat Body fat estimated through Bioelectrical Impedance Analyzer (BIA) according 
to manufacturer’s algorithm (BIA 103, JRL systems, single-frequency analyzer, 
Detroit, USA) 
Yes No 
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Table S3. Information about the studies from which weights for GRSs were derived 
















Predicted visceral adiposity 
trait (VAT) 
Karlsson et al 2019 
UKBiobank, 
n=325,153 
White and British 
ancestry  
GRS-BF81 
Body fat mass; measured 
with bio-electrical impedance 
(BIA) and dual energy X-ray 
absorptiometry (DXA 




White and British 
ancestry of UKBB 
Legend: GRS-VAT208, Genetic risk score for Visceral Adipose Tissue based on 208 SNPs; GRS-BF81, Genetic risk score for Body 
Fat based on 81 SNPs; GRS-WHR324 Genetic Risk Score for Waist Hip Ratio based on 324 SNPs; GRS-BMI565, Genetic Risk 
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Table S4 Association of four GRS with blood pressure traits in MPP (a.) and in MDC (b.) 
a. MPP SBP at baseline (n=9,140) DBP at baseline (n=9,140) 
Model 1 Model 2 Model 1 Model 2 
Beta (95%CI) p-value Beta (95%CI) Beta (95%CI) p-value Beta (95%CI) p-value
GRS-BMI565 0.231 (0.131,0.331) 3.4E-6 0.233 (0.133,0.333) 4.2E-6 0.251 (0.153,0.349) 4.0E-7 0.257 (0.157,0.357) 3.0E-7 
GRS-WHR324 0.426 (0.175,0.677) 0.001 0.288 (0.123,0.453) 0.001 0.529 (0.286,0.772) 3.24E-5 0.367 (0.202,0.532) 1.4E-5 
GRS-BF81 0.247 (-0.07,0.563) 0.125 0.241 (-0.07,0.552) 0.130 0.275 (-0.036,0.586) 0.084 0.269 (-0.017,0.576) 0.087 
GRS-VAT208 0.326 (0.173,0.479) 3.1E-5 0.336 (0.187,0.485) 9.7E-6 0.270 (0.162,0.378) 0.001 0.296 (0.149,0.443) 8.3E-5 
SBP at follow-up (n=9,041) DBP at follow-up (n=9,041) 
GRS-BMI565 0.163 (0.060,0.260) 0.002 0.158 (0.058,0.258) 0.002 0.178 (0.078,0.278) 0.001 0.172 (0.072,0.272) 0.001 
GRS-WHR324 0.083 (-0.146,0.312) 0.475 0.048 (-0.050,0.196) 0.053 0.061 (-0.089,0.211) 0.431 0.055 (-0.098,0.208) 0.477 
GRS-BF81 -0.166 (-0.497,0.165) 0.327 -0.161 (-0.482,0.160) 0.325 -0.034 (-0.353,0.285) 0.834 -0.033 (-0.343,0.277) 0.834 
GRS-VAT208 0.128 (-0.029,0.285) 0.110 0.122 (-0.042,0.286) 0.111 0.200 (0.043,0.357) 0.012 0.190 (0.04,0.339) 0.012 
b. MDC SBP at baseline (n=29,247) DBP at baseline (n=29,247) 
GRS-BMI565 0.166 (0.104,0.222) 4.0E-8 0.205 (0.145,0.265) 8.3E-12 0.239 (0.18,0.298) 4.4E-16 0.248 (0.188,0.308) 6.8E-17 
GRS-WHR324 0.620 (0.336,0.940) 2.0E-5 0.546 (0.311,0.781) 5.7E-6 0.767 (0.477,1.057) 2.5E-7 0.676 (0.431,0.921) 6.0E-8 
GRS-BF81 0.129 (0.094,0.164) 0.310 0.142 (-0.038,0.322) 0.305 0.311 (0.274,0.348) 0.02 0.267 (0.089,0.445) 0.003 
GRS-VAT208 0.182 (0.096,0.268) 3.3E-5 0.226 (0.142,0.310) 1.6E-7 0.267(0.183,0.351) 7.6E-10 0.284 (0.200,0.368) 3.1E-11 
Legend: GRS-VAT208, Genetic risk score for Visceral Adipose Tissue based on 208 SNPs; GRS-BF81, Genetic risk score for Body Fat based on 81 SNPs; GRS-WHR324 Genetic 
Risk Score for Waist Hip Ratio based on 324 SNPs; GRS-BMI565, Genetic Risk Score for Body Mass Index based on 565 SNPs; BMI, Body Mass Index; BF, Body Fat; WHR, 
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OR (95%CI) p-value 
GRS565-BMI 1.49 (1.32,1.68) 1.0E
-10 
GRS324-WHR 2.55 (1.51,4.35) 0.001 
Legend: GRS-WHR324 Genetic Risk Score for Waist Hip Ratio based on 324 SNPs; GRS-BMI565, Genetic Risk Score for Body 
Mass Index based on 565 SNPs. 







OR (95%CI) p-value OR (95%CI) p-value 
GRS-BMI565 1.59 (1.04,2.03) 0.0002 1.42 (1.03,1.96) 0.003 
GRS-WHR324 2.49 (1.52,4.08) 0.0003 1.10 (0.54,2.25) n.s.
GRS-BF81 1.64 (0.66,4.06) n.s. 0.41 (0.15,1.11) n.s.
GRS-VAT208 2.47 (1.64,3.72) 1.5e-05 1.42 (0.89,2.23) 0.01 
Legend: GRS-VAT208, Genetic risk score for Visceral Adipose Tissue based on 208 SNPs; GRS-BF81, Genetic risk score for Body 
Fat based on 81 SNPs; GRS-WHR324 Genetic Risk Score for Waist Hip Ratio based on 324 SNPs; GRS-BMI565, Genetic Risk 
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Table S7 Summarized data analysis 
SBP DBP 
Method Estimate(95%CI) p-value Estimate(95%CI) p-value
GRS-BMI565 
Weighted median 1.90(0.09,3.71) 0.04 2.05(1.15,2.95) <0.0001 
IVW 2.75(1.66,3.85) <0.0001 2.00(1.45,2.55) <0.0001 
MR Egger 1.79(-1.15,4.73) n.s. 1.32(-0.15,2.81) n.s.
GRS-WHR324 
Weighted median 4.67(2.57,7.08) <0.0001 2.44(1.23,3.65) <0.0001 
IVW 3.18(1.68,4.67) <0.0001 1.95(1.19,2.71) <0.0001 
MR Egger 4.25(1.68,4.67) 0.03 2.51(0.54,4.47) 0.012 
GRS-BF81 
Weighted median 0.19(-0.02,0.40) n.s. 0.18(-0.04,0.39) n.s.
IVW 0.08(-0.10,0.25) n.s. 0.19(-0.01,0.38) n.s.
MR Egger 0.13(-0.11,0.37) n.s. 0.12(-0.14,0.38) n.s.
GRS-VAT208 
Weighted median 0.15(0.05,0.24) 0.003 0.18(0.08,0.28) <0.0001 
IVW 0.13(0.06,0.20) <0.0001 0.19(0.12,0.26) <0.0001 
MR Egger 0.13(-0.10,0.36) n.s. 0.21(-0.03,0.44) n.s.
Legend: DBP, Diastolic Blood Pressure; GRS-VAT208, Genetic risk score for Visceral Adipose Tissue based on 208 
SNPs; GRS-BF81, Genetic risk score for Body Fat based on 81 SNPs; GRS-WHR324 Genetic Risk Score for Waist 
Hip Ratio based on 324 SNPs; GRS-BMI565, Genetic Risk Score for Body Mass Index based on 565 SNPs; IVW, 
Inverse Weighted Median; SBP, Systolic Blood Pressure. 
Table S8 Association with hypertension prevalence in MDC, after stratification for age 
Age groups* OR (95%CI) p-value 
GRS-BMI565 1st tertile age 
2nd tertile age 







GRS-WHR324 1st tertile age 
2nd tertile age 







GRS-BF81 1st tertile age 
2nd tertile age 







GRS-VAT208 1st tertile age 
2nd tertile age 







Legend: GRS-VAT208, Genetic risk score for Visceral Adipose Tissue based on 208 SNPs; GRS-BF81, Genetic risk score for Body 
Fat based on 81 SNPs; GRS-WHR324 Genetic Risk Score for Waist Hip Ratio based on 324 SNPs; GRS-BMI565, Genetic Risk 
Score for Body Mass Index based on 565 SNPs; OR Odd Ratio; CI; Confidence Interval. * 1st tertile: from 44.9 to 53.3 years; 2nd 
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Supplementary Figures 
Figure S1 Association of the four GRSs with the adiposity traits, in the two cohorts 
Legend: GRS-VAT208, Genetic risk score for Visceral Adipose Tissue based on 208 SNPs; GRS-BF81, Genetic risk 
score for Body Fat based on 81 SNPs; GRS-WHR324 Genetic Risk Score for Waist Hip Ratio based on 324 SNPs; 
GRS-BMI565, Genetic Risk Score for Body Mass Index based on 565 SNPs; BMI, Body Mass Index; BF, Body Fat; 
WHR, Waist Hip Ratio. The Forest plot shows the magnitude of the association of 1 SD of the different GRS with the 
correspondent adiposity trait in the Malmö Preventive Project (MPP) and in the Malmö Diet and Cancer (MDC). I.e. for 
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Figure S3 Comparison of different summarized-level data methods in the association of GRS-WHR324 with SBP (a.) a
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Figure S5 Comparison of different summarized-level data methods in the association of GRS-VAT208 with SBP (a.) 




 http://ahajournals.org by on June 28, 2021
12 
Figure S6 Association of the four GRSs with the prevalence of hypertension in the MDC after stratification for age. 
Legend: GRS-VAT208, Genetic risk score for Visceral Adipose Tissue based on 208 SNPs; GRS-BF81, Genetic risk 
score for Body Fat based on 81 SNPs; GRS-WHR324 Genetic Risk Score for Waist Hip Ratio based on 324 SNPs; 
GRS-BMI565, Genetic Risk Score for Body Mass Index based on 565 SNPs; BMI, Body Mass Index; BF, Body Fat; 
WHR, Waist Hip Ratio. The Forest plot shows the magnitude of the association of 1 SD of the different GRS with the 
correspondent adiposity trait in the Malmö Diet and Cancer (MDC). I.e. for each SD increase in GRS-VAT208 there is 
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